<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>359-MIRABEGRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIRABEGRON" rxcui="1300786">
<ATC code="G04BD12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the flecainide by decrease of its metabolism by the mirabegron</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the flecainide during the administration of these medications together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>359-MIRABEGRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIRABEGRON" rxcui="1300786">
<ATC code="G04BD12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
<ATC code="C07FB02" />
<ATC code="C07CB02" />
<ATC code="C07BB02" />
<ATC code="C07BB52" />
<ATC code="C07AB52" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the metoprolol used in heart failure, increase of the plasma concentrations of the metoprolol due to decrease of its metabolism by the mirabegron</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the metoprolol during the administration of these medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>359-MIRABEGRON.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="MIRABEGRON" rxcui="1300786">
<ATC code="G04BD12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the propafenone by decrease of its metabolism by the mirabegron</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible reduction of the dosage of the propafenone during the administration with the mirabegron</COMMENT>
</INTERACTION>
</INTERACTIONS>
